Media Coverage
Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.
Psychiatric drugs were once a $30 billion business. Analysts say these 9 companies could revive it.
BioSpace Movers & Shakers, May 7
Karyopharm taps longtime Pfizer, Amgen vet to steer the ship; With Merck in the rearview mirror, Roger Perlmutter stakes his claim to a CEO job — and it's a surprising choice
Chutes & Ladders—Former Merck R&D chief Perlmutter takes reins at Eikon, applying Nobel-winning tech to drug discovery
To read the full story, subscribe or sign in. Appointments and advancements for May 4, 2021
New data shows strength in VistaGen’s PH94B for SAD
A Potential Benzodiazepine Replacement
Shawn Singh of VistaGen Therapeutics: 5 Ways That Businesses Can Help Promote The Mental Wellness Of Their Employees
VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder
